Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosnilimab in moderate to severe rheumatoid arthritis
NCT06041269Phase 2Active, not recruiting
- Sponsor
- AnaptysBio, Inc.
- Start
- Aug 2023
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of rosnilimab in rheumatoid arthritis (RA), sponsored by AnaptysBio, Inc.. Started Aug 2023; status: active, not recruiting.
02
Drugs
rosnilimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06041269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06041269.